Valeant Pharmaceuticals International (NYSE:VRX)

CAPS Rating: 3 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar DocRiggs (54.01) Submitted: 4/2/2014 2:21:46 PM : Outperform Start Price: $132.38 VRX Score: -6.69

MF One

Recs

0
Member Avatar RLBOWERSOX (96.19) Submitted: 3/31/2014 4:40:45 PM : Outperform Start Price: $132.07 VRX Score: -6.93

One of the final four

Recs

0
Member Avatar mrwrong (< 20) Submitted: 3/29/2014 2:06:48 PM : Underperform Start Price: $129.27 VRX Score: +5.45

growth will stall as company comes a cropper, with a bridge too far. most all- do, but i like it now.

Recs

0
Member Avatar motto1628 (< 20) Submitted: 3/25/2014 4:05:57 PM : Outperform Start Price: $132.26 VRX Score: -7.38

- genius CEO in acquisition
- diversified pharmaceutical products
- stock advisor pick

Recs

0
Member Avatar Sunchaser101 (< 20) Submitted: 3/15/2014 9:38:03 AM : Outperform Start Price: $140.60 VRX Score: -13.62

Valiant has the best business plan I have ever reviewed for a Pharma Co. They reduce their cost, risk, prduct liability, while increasing flexiblity, ability to control overhead, focus on sales and distribution which is where the profit is located. It also enhances their ability to accuratley forcast future cash flow, product viability by area and need. It provides them with statistics on employee performance, training needs and promotability. They have the best of both worlds by eliminating cost & liability on the front end and enhancing predictability and efficiency on the middle and back end.

Recs

0
Member Avatar mtbound (33.27) Submitted: 3/1/2014 12:25:37 PM : Outperform Start Price: $143.30 VRX Score: -15.75

I'm here mainly because of leadership. I've bought in to extraordinary leadership extracting value.

Recs

0
Member Avatar lapinkpanther (51.32) Submitted: 2/24/2014 2:58:06 PM : Outperform Start Price: $145.96 VRX Score: -16.81

Great Management!

Recs

0
Member Avatar bradrimm (21.37) Submitted: 2/9/2014 9:55:01 AM : Outperform Start Price: $138.21 VRX Score: -15.42

Strips dead wood. Value adding. Good macro scene

Recs

0
Member Avatar mercury14 (< 20) Submitted: 1/24/2014 11:02:41 PM : Underperform Start Price: $132.48 VRX Score: +11.97

Hmmm...on the balance sheet, MF shows "intangibles" rose 8-fold from 2009 to 2013...really?

Recs

0
Member Avatar chris293 (87.15) Submitted: 1/22/2014 7:16:14 PM : Outperform Start Price: $137.06 VRX Score: -12.60

Everyone wants the newest drugs of course. Even if they don't need them.

Recs

0
Member Avatar GVFool15 (60.82) Submitted: 1/22/2014 3:00:32 PM : Outperform Start Price: $132.51 VRX Score: -9.41

They're becoming a large pharmaceutical company, building an empire of products and people that will propel this company to outperform the market over the next 5 years.

Recs

14
Member Avatar jpimp (< 20) Submitted: 1/10/2014 7:35:06 PM : Outperform Start Price: $131.93 VRX Score: -9.05

My grandfather read an article about Valeant in the Montreal Gazette this morning, after reading the article he is convinced Valeants growth is unrealistic and that they are cooking their books. My grandfather is always wrong… about everything.
I bought 50 shares immediately.

Recs

0
Member Avatar huddaman (97.35) Submitted: 12/31/2013 1:19:29 PM : Outperform Start Price: $117.62 VRX Score: +2.66

One of my top 5 picks from SA 2014 Challenge

Recs

0
Member Avatar possumj (< 20) Submitted: 12/25/2013 3:00:56 PM : Outperform Start Price: $113.51 VRX Score: +5.86

More information on three D printing stocks

Recs

0
Member Avatar Mark239 (78.07) Submitted: 12/23/2013 10:39:05 PM : Outperform Start Price: $112.30 VRX Score: +6.57

Growth Company

Recs

0
Member Avatar alfred13 (89.95) Submitted: 12/11/2013 3:58:18 PM : Outperform Start Price: $106.49 VRX Score: +10.32

Acquiring Baush & Lomb was a good move. Seems well set up for consistent earnings at good rate of growth.

Recs

0
Member Avatar Charlotte49er (82.07) Submitted: 12/7/2013 12:54:57 PM : Outperform Start Price: $108.63 VRX Score: +9.64

Growing through smart acquisitions.

Recs

2
Member Avatar TMFRedRaider (70.70) Submitted: 11/12/2013 2:19:36 PM : Outperform Start Price: $105.72 VRX Score: +9.91

Great management, solid strategy, and very attractive valuation. Recent drop makes valuation even more enticing.

Recs

0
Member Avatar lovepeace (35.72) Submitted: 10/27/2013 5:03:24 PM : Outperform Start Price: $113.69 VRX Score: +0.51

While everyone else is focused on biotech, Valeant scoops up Bausch and Lomb. From their webpage:

On August 5, 2013, Valeant Pharmaceuticals International, Inc., completed its acquisition of Bausch + Lomb. Valeant's existing ophthalmology businesses have been integrated into the Bausch + Lomb division to create a global eye health platform. The united business has a vast eye care product portfolio and a full array of innovative, late stage over-the-counter, prescription and ophthalmic surgery products in the development pipeline.

Recs

0
Member Avatar Mgruggie (96.53) Submitted: 10/25/2013 10:21:44 AM : Outperform Start Price: $112.90 VRX Score: +1.84

SA pick

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement